

Ontario Public Drug Programs

Drug Submission Status

Report for March 2018

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Fluoxetine	Prozac	fluoxetine HCl	20mg/5mL	oral solution	02231328
Dr. Reddy's Laboratories Canada Inc.	Reddy-Progesterone	Prometrium	progesterone	100mg	capsule	02463113
Marcan Pharmaceuticals Inc.	Mar-Rizatriptan ODT	Maxalt RPD	rizatriptan benzoate	5mg	orally disintegrating tablets	02462788
Marcan Pharmaceuticals Inc.	Mar-Rizatriptan ODT	Maxalt RPD	rizatriptan benzoate	10mg	orally disintegrating tablet	02462796